Form 4: Director Roy D. Baynes Executes Travere Stock Options

Director Roy D. Baynes exercised 4,500 stock options and sold the resulting shares of Travere Therapeutics, Inc. (TVTX).

Summary

• Director Roy D. Baynes exercised 4,500 stock options at a strike price of $21.38 per share.
• Following the exercise, the director sold the 4,500 shares at a price of $50.00 per share.
• The transactions were executed on June 12, 2026, pursuant to a Rule 10b5-1(c) trading plan adopted on November 17, 2025.
• The director's direct beneficial ownership of common stock changed from 46,000 to 41,500 shares following the sale.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was executed under a pre-established 10b5-1 plan, which is a routine administrative action.

Positives

• The transaction was pre-planned under a Rule 10b5-1(c) plan, indicating the sale was not based on non-public information.

Negatives

• The director reduced their total direct equity stake in the company by 4,500 shares.

Risks

• None identified in this filing.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via pre-arranged 10b5-1 plans is standard corporate practice and generally does not signal a lack of confidence in company fundamentals.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard industry practice for corporate insiders to manage equity holdings while avoiding potential conflicts with insider trading regulations.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and represents a small portion of the director's holdings.

Key Dates

Keywords

Travere Therapeutics, TVTX, Insider Trading, Form 4, Stock Options, Roy D. Baynes